- Previously served at Allergan as a Vice President for Sales & Marketing, member of Operational Leadership Team
- Worked on several leading dermatology brands including ACZONE® and BOTOX® during 15-year career at Allergan
MENLO PARK, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the appointment of Lori Lyons-Williams as Chief Commercial Officer. In this new role, Lori will be responsible for developing and implementing the commercial strategy for Dermira’s Phase 3 product candidates: CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. as a treatment for moderate-to-severe chronic plaque psoriasis; DRM04, in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and olumacostat glasaretil (formerly DRM01), in development for acne vulgaris.
“I am thrilled that Lori has joined Dermira at an important time, as we begin to transition from a company solely focused on product development to one preparing to commercialize three products,” said Tom Wiggans, chairman and chief executive officer of Dermira. “Lori is a well-regarded and respected sales and marketing professional who has excelled at every level throughout her career. Her experience working on highly successful dermatology brands and in building a fully integrated commercial team makes her particularly well-suited to bring what we believe is an exciting portfolio of products to healthcare professionals and their patients.”
Lori brings nearly 19 years of commercial experience to Dermira. Prior to joining Dermira, she spent 15 years in positions of increasing responsibility within the sales and marketing organization at Allergan, most recently as Vice President, Sales & Marketing for the Urology franchise. In this role, she helped to build what ultimately became one of Allergan’s fastest growing business units, and served as a member of the Allergan Commercial Leadership Team as well as the Operational Leadership Team. In previous roles within Allergan, she served as Product Director for Allergan’s medical dermatology brands and also held senior-level positions on the ACZONE® and BOTOX® marketing teams. Lori began her career at Johnson & Johnson as a pharmaceutical sales representative.
“I am delighted to be joining an organization with an experienced leadership team and three promising late-stage candidates that could one day potentially provide meaningful clinical benefit to millions of patients with dermatologic conditions,” said Lyons-Williams. “Dermira’s innovative approach, commitment to differentiation, and dedication to foster scientific advancement in dermatological conditions is refreshing. I am eager to play a role in generating commercial successes and excited to build a best-in-class team.”
Lori holds a BA in Interdisciplinary Studies from Virginia Tech and an MBA from the Carlson School of Management of the University of Minnesota.
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three Phase 3 product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and olumacostat glasaretil, in development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements with respect to Dermira’s potential commercialization of its product candidates; Dermira’s ability to bring its portfolio of products to healthcare professionals and their patients and to potentially provide meaningful clinical benefit to millions of patients with dermatologic conditions; Dermira’s anticipated commercial efforts and successes; and the building of a best-in-class team. These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the design, implementation and outcomes of Dermira’s clinical trials; the outcomes of Dermira’s future meetings with regulatory agencies; Dermira’s dependence on third-party clinical research organizations, manufacturers and suppliers; Dermira’s ability to attract and retain key employees; Dermira’s ability to obtain necessary additional capital; and Dermira’s ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Dermira’s forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this press release. Dermira undertakes no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
Senior Director, Head of Corporate Communications
Chief Operating Officer and Chief Financial Officer
Robert H. Uhl